See more : CAA Resources Limited (2112.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Anika Therapeutics, Inc. (ANIK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Anika Therapeutics, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- China Logistics Property Holdings Co., Ltd (1589.HK) Income Statement Analysis – Financial Results
- CAQ Holdings Limited (CAQ.AX) Income Statement Analysis – Financial Results
- Hennessy Capital Investment Corp. V (HCIC) Income Statement Analysis – Financial Results
- Lendlease Group (LLESF) Income Statement Analysis – Financial Results
- Suzhou Douson Drilling & Production Equipment Co.,Ltd. (603800.SS) Income Statement Analysis – Financial Results
Anika Therapeutics, Inc. (ANIK)
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 166.66M | 156.24M | 147.79M | 130.46M | 114.61M | 105.56M | 113.42M | 103.38M | 93.00M | 105.59M | 75.08M | 71.36M | 64.78M | 55.56M | 40.14M | 35.78M | 30.83M | 26.84M | 29.84M | 26.47M | 15.40M | 13.19M | 11.31M | 16.34M | 13.50M | 13.90M | 12.00M | 1.20M | 3.40M | 4.70M | 2.20M |
| Cost of Revenue | 63.57M | 62.66M | 64.85M | 61.43M | 28.75M | 31.28M | 27.36M | 24.03M | 21.05M | 20.93M | 22.77M | 28.99M | 26.78M | 23.83M | 13.67M | 13.19M | 11.88M | 11.12M | 11.14M | 9.95M | 8.01M | 8.11M | 8.23M | 8.67M | 5.30M | 5.20M | 4.40M | 700.00K | 2.80M | 3.70M | 1.90M |
| Gross Profit | 103.09M | 93.58M | 82.94M | 69.03M | 85.86M | 74.28M | 86.06M | 79.35M | 71.95M | 84.66M | 52.32M | 42.37M | 37.99M | 31.73M | 26.47M | 22.59M | 18.95M | 15.72M | 18.69M | 16.52M | 7.40M | 5.08M | 3.08M | 7.66M | 8.20M | 8.70M | 7.60M | 500.00K | 600.00K | 1.00M | 300.00K |
| Gross Profit Ratio | 61.85% | 59.89% | 56.12% | 52.91% | 74.92% | 70.37% | 75.87% | 76.76% | 77.36% | 80.18% | 69.68% | 59.38% | 58.65% | 57.11% | 65.94% | 63.14% | 61.46% | 58.58% | 62.65% | 62.41% | 48.03% | 38.51% | 27.26% | 46.91% | 60.74% | 62.59% | 63.33% | 41.67% | 17.65% | 21.28% | 13.64% |
| Research & Development | 32.69M | 28.18M | 27.33M | 23.43M | 16.67M | 18.19M | 18.79M | 10.73M | 8.99M | 8.14M | 7.06M | 5.39M | 6.17M | 6.87M | 8.18M | 7.40M | 4.36M | 3.62M | 4.73M | 4.09M | 2.60M | 3.93M | 4.28M | 3.26M | 4.20M | 2.00M | 2.00M | 0.00 | 1.30M | 1.50M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 34.34M | 21.54M | 18.01M | 14.83M | 15.07M | 12.94M | 14.73M | 17.86M | 17.32M | 10.55M | 10.97M | 8.00M | 6.68M | 5.41M | 6.04M | 4.21M | 4.42M | 6.21M | 4.19M | 3.00M | 2.70M | 2.10M | 0.00 | 900.00K | 700.00K | 1.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 95.85M | 84.79M | 74.10M | 60.06M | 34.95M | 34.34M | 21.54M | 18.01M | 14.83M | 15.07M | 12.94M | 14.73M | 17.86M | 17.32M | 10.55M | 10.97M | 8.00M | 6.68M | 5.41M | 6.04M | 4.21M | 4.42M | 6.21M | 4.19M | 3.00M | 2.70M | 2.10M | 2.60M | 900.00K | 700.00K | 1.90M |
| Other Expenses | 62.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.54B | 0.00 | 0.00 | 2.15B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.20M | 1.10M | 800.00K | 300.00K | 600.00K | 300.00K | 200.00K | 300.00K |
| Operating Expenses | 191.48M | 112.98M | 101.42M | 83.49M | 51.62M | 52.53M | 40.33M | 28.75M | 23.81M | 23.22M | 20.00M | 20.12M | 24.03M | 24.19M | 18.73M | 18.36M | 12.36M | 10.30M | 10.14M | 10.13M | 6.80M | 8.35M | 10.49M | 8.65M | 8.30M | 5.50M | 4.40M | 3.20M | 2.50M | 2.40M | 2.20M |
| Cost & Expenses | 254.30M | 175.64M | 166.27M | 144.93M | 80.36M | 83.81M | 67.69M | 52.77M | 44.87M | 44.15M | 42.76M | 49.11M | 50.81M | 48.02M | 32.40M | 31.55M | 24.24M | 21.41M | 21.28M | 20.08M | 14.81M | 16.46M | 18.72M | 17.32M | 13.60M | 10.70M | 8.80M | 3.90M | 5.30M | 6.10M | 4.10M |
| Interest Income | 0.00 | 654.00K | 188.00K | 498.00K | 1.87M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 186.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 654.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 127.19K | 5.26M | 182.39K | 194.62K | 4.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 14.22M | 16.35M | 15.99M | 15.00M | 7.17M | 5.91M | 4.29M | 3.73M | 3.78M | 4.71M | 4.77M | 4.53M | 4.00M | 3.32M | 1.29M | 1.43M | 818.73K | 384.06K | 459.00K | 710.00K | 1.01M | 1.10M | 1.23M | 1.20M | 1.10M | 800.00K | 300.00K | 600.00K | 300.00K | 200.00K | 300.00K |
| EBITDA | -11.23M | -4.91M | 2.62M | -12.83M | 34.25M | 27.66M | 50.02M | 54.34M | 51.91M | 61.45M | 32.03M | 26.78M | 17.97M | 10.86M | 11.18M | 5.66M | 7.41M | 5.81M | 9.01M | 14.53M | 1.60M | -2.18M | -6.18M | 214.38K | 1.10M | 3.37M | 3.50M | -2.10M | -1.60M | -1.20M | -1.60M |
| EBITDA Ratio | -6.74% | -12.42% | -26.78% | -0.47% | 29.88% | 20.60% | 40.32% | 48.95% | 51.76% | 58.19% | 42.66% | 34.74% | 27.74% | 19.54% | 27.87% | 15.82% | 24.02% | 21.65% | 30.20% | 26.82% | 10.39% | -16.53% | -54.61% | 1.31% | 5.93% | 19.42% | 26.67% | -183.33% | -47.06% | -27.66% | -72.73% |
| Operating Income | -87.64M | -19.40M | -18.48M | -14.47M | 34.25M | 21.75M | 45.73M | 50.61M | 48.13M | 61.45M | 32.61M | 19.72M | 13.97M | 7.54M | 5.59M | 4.23M | 6.59M | 5.43M | 8.55M | 6.39M | 595.00K | -3.27M | -7.41M | -983.37K | -100.00K | 3.20M | 3.20M | -2.70M | -1.90M | -1.40M | -1.90M |
| Operating Income Ratio | -52.58% | -12.42% | -12.50% | -11.09% | 29.88% | 20.60% | 40.32% | 48.95% | 51.76% | 58.19% | 43.43% | 27.63% | 21.56% | 13.57% | 13.92% | 11.81% | 21.37% | 20.22% | 28.66% | 24.14% | 3.86% | -24.83% | -65.51% | -6.02% | -0.74% | 23.02% | 26.67% | -225.00% | -55.88% | -29.79% | -86.36% |
| Total Other Income/Expenses | 2.31M | 654.00K | -188.00K | -302.00K | 1.87M | 1.46M | 473.00K | 263.00K | 120.00K | 58.14K | -127.00K | -187.78K | -182.39K | -194.62K | -2.23M | 498.51K | 2.10M | 2.10M | 1.24M | 388.71K | 144.00K | 239.00K | 662.19K | 1.17M | 1.38M | 700.00K | 200.00K | 100.00K | 0.00 | 100.00K | 0.00 |
| Income Before Tax | -85.33M | -18.75M | 2.43M | -28.62M | 36.12M | 23.21M | 46.20M | 50.87M | 48.25M | 61.51M | 32.48M | 19.53M | 13.79M | 7.34M | 5.51M | 4.73M | 8.69M | 7.53M | 9.79M | 6.78M | 739.00K | -3.03M | -6.75M | 189.49K | -100.00K | 4.40M | 3.40M | -2.60M | 0.00 | -1.30M | -1.90M |
| Income Before Tax Ratio | -51.20% | -12.00% | 1.64% | -21.94% | 31.52% | 21.99% | 40.74% | 49.21% | 51.89% | 58.25% | 43.26% | 27.37% | 21.28% | 13.22% | 13.73% | 13.21% | 28.18% | 28.05% | 32.82% | 25.61% | 4.80% | -23.02% | -59.66% | 1.16% | -0.74% | 31.65% | 28.33% | -216.67% | 0.00% | -27.66% | -86.36% |
| Income Tax Expense | -2.66M | -3.89M | -1.71M | -4.64M | 8.93M | 4.49M | 14.39M | 18.32M | 17.50M | 23.19M | 11.91M | 7.77M | 5.32M | 3.03M | 1.82M | 1.10M | 2.65M | 2.92M | 3.90M | -4.41M | -88.00K | 5.00K | 9.08K | 15.94K | 2.20M | 100.00K | 100.00K | -100.00K | 100.00K | -100.00K | -300.00K |
| Net Income | -82.67M | -14.86M | 4.13M | -23.98M | 27.19M | 18.72M | 31.82M | 32.55M | 30.76M | 38.32M | 20.57M | 11.76M | 8.47M | 4.32M | 3.69M | 3.63M | 6.04M | 4.60M | 5.89M | 11.19M | 827.00K | -3.04M | -6.76M | 173.55K | -2.50M | 4.30M | 3.30M | -2.70M | -2.00M | -1.40M | -1.60M |
| Net Income Ratio | -49.60% | -9.51% | 2.80% | -18.38% | 23.73% | 17.74% | 28.05% | 31.48% | 33.07% | 36.29% | 27.40% | 16.48% | 13.07% | 7.77% | 9.19% | 10.14% | 19.58% | 17.15% | 19.75% | 42.28% | 5.37% | -23.05% | -59.74% | 1.06% | -18.52% | 30.94% | 27.50% | -225.00% | -58.82% | -29.79% | -72.73% |
| EPS | -5.64 | -1.02 | 0.29 | -1.69 | 1.93 | 1.30 | 2.18 | 2.22 | 2.06 | 2.61 | 1.46 | 0.89 | 0.65 | 0.34 | 0.32 | 0.32 | 0.55 | 0.43 | 0.57 | 0.98 | 0.08 | -0.31 | -0.68 | 0.02 | -0.26 | 0.38 | 0.60 | -0.56 | -0.61 | -0.45 | -0.51 |
| EPS Diluted | -5.64 | -1.02 | 0.28 | -1.69 | 1.89 | 1.27 | 2.11 | 2.15 | 2.01 | 2.51 | 1.39 | 0.82 | 0.62 | 0.32 | 0.32 | 0.32 | 0.53 | 0.41 | 0.52 | 0.98 | 0.08 | -0.31 | -0.68 | 0.02 | -0.24 | 0.34 | 0.44 | -0.56 | -0.61 | -0.45 | -0.51 |
| Weighted Avg Shares Out | 14.66M | 14.56M | 14.40M | 14.22M | 14.12M | 14.44M | 14.58M | 14.68M | 14.93M | 14.68M | 14.09M | 13.26M | 13.06M | 12.62M | 11.39M | 11.31M | 11.06M | 10.64M | 10.41M | 11.42M | 9.95M | 9.93M | 9.93M | 9.87M | 9.74M | 9.89M | 5.00M | 4.82M | 3.28M | 3.11M | 3.14M |
| Weighted Avg Shares Out (Dil) | 14.66M | 14.56M | 14.63M | 14.22M | 14.37M | 14.69M | 15.07M | 15.12M | 15.32M | 15.27M | 14.83M | 14.34M | 13.75M | 13.65M | 11.56M | 11.46M | 11.45M | 11.16M | 11.43M | 11.42M | 10.85M | 9.93M | 9.93M | 10.04M | 10.22M | 11.01M | 7.50M | 4.82M | 3.28M | 3.11M | 3.14M |
Anika Receives FDA 510(k) Clearance for the X-Twist™ Knotless Fixation System, Expanding its Sports Medicine Soft Tissue Portfolio
X-Twist provides a simple, versatile knotless suture anchor system ideal for key repairs in the shoulder, foot and ankle, and other extremities X-Twist provides a simple, versatile knotless suture anchor system ideal for key repairs in the shoulder, foot and...
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on May 2, 2022, Anika granted non-statutory stock options (“Options”) covering an aggregate of 13,091...
Anika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q1 2022 Results - Earnings Call Transcript
Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Mark Namaroff - VP, IR, ESG and Corporate Communications Cheryl Blanchard - President and CEO Mike Levitz - EVP, CFO and Treasurer...
Anika Reports First Quarter Fiscal 2022 Financial Results
First quarter revenue growth of 7% year-over-year driven by favorable order timing in OA Pain Management First quarter revenue growth of 7% year-over-year driven by favorable order timing in OA Pain Management
New Strong Sell Stocks for April 26th
ANIK, ALIM, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2022
New Strong Sell Stocks for April 19th
ANIK, APP, and ARCE have been added to the Zacks Rank #5 (Strong Sell) List on April 19, 2022.
Anika to Issue First Quarter 2022 Financial Results on Thursday, May 5, 2022
BEDFORD, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its first quarter 2022 financial results after the close of...
New Strong Sell Stocks for April 7th
AMPE, ANIK, and FAT have been added to the Zacks Rank #5 (Strong Sell) List on April 7, 2022.
Anika to Participate in the 21st Annual Needham Virtual Healthcare Conference
BEDFORD, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14,...
New Strong Sell Stocks for April 4th
AKU, ANIK, and AY have been added to the Zacks Rank #5 (Strong Sell) List on April 4, 2022.
Source: https://incomestatements.info
Category: Stock Reports